NASDAQ:SLDB

Solid Biosciences Q1 2025 Earnings Results & Report

Solid Biosciences logo
$6.23 -0.25 (-3.86%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.01 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Solid Biosciences missed analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.59 versus the -$0.53 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
3:00 AM ET

Solid Biosciences EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Q1 2025 Earnings FAQ

Solid Biosciences (NASDAQ:SLDB) reported earnings of -$0.59 per share for Q1 2025, missing the consensus estimate of -$0.53. The report was announced on Thursday, May 15, 2025.

Solid Biosciences Earnings Headlines

William Blair Begins Coverage on Solid Biosciences (NASDAQ:SLDB)
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions.

Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.

Founded in 2013 and based in the United States, Solid Biosciences conducts research and clinical development in the rare-disease field. Its work includes evaluating investigational treatments through clinical studies.

View Solid Biosciences Profile